
Roche

Roche

2017 results

London, 01 February 2018

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1 pricing and product initiatives of competitors;
2 legislative and regulatory developments and economic conditions;
3 delay or inability in obtaining regulatory approvals or bringing products to market;
4 fluctuations in currency exchange rates and general financial market conditions;
5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6 increased government pricing pressures;
7 interruptions in production;
8 loss of or inability to obtain adequate protection for intellectual property rights;
9 litigation;
10 loss of key executives or other employees; and
11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com

Group

Severin Schwan
Chief Executive Officer

2017 performance

Outlook

2017: Targets fully achieved

Targets for 2017		*FY 2017*	
Group sales growth[1]	Mid-single digit (raised at HY)	**+5%**	✓
Core EPS growth[1]	Broadly in line with sales growth	**+5%**	✓
Dividend outlook	Further increase dividend in Swiss francs[2]	**CHF 8.30**	✓

[1] At constant exchange rates (CER); [2] 2017 dividend as proposed by the Board of Directors

2017: Good sales growth in both divisions

	2017 CHFbn	2016 CHFbn	Change in % CHF	Change in % CER
Pharmaceuticals Division	**41.2**	39.1	**5**	**5**
Diagnostics Division	**12.1**	11.5	**5**	**5**
Roche Group	**53.3**	50.6	**5**	**5**

CER=Constant Exchange Rates

2017: Sales growth for the sixth consecutive year



All growth rates at Constant Exchange Rates (CER)

2017: Strong sales growth in US and International



All growth rates at Constant Exchange Rates (CER)

2017: Successful launch activities
Differentiation driving growth



- EU / US approval, NCCN guidelines category '1'
- US approval in Her2+ mBC, eBC & neoadjuvant
- US / EU approval in bladder (1/2L) & lung (2L)
- US / EU / CH / Australia approval in RMS and PPMS

mBC=metastatic breast cancer; eBC=early breast cancer; PPMS=primary progressive multiple sclerosis; RMS=relapsing forms of multiple sclerosis; NCCN=National Comprehensive Cancer Network;

2017: Unprecedented pipeline advances

Approvals (US & EU)



Major approvals:

- **HER2:** Perjeta APHINITY (eBC) - US
- **CD20:** Gazyva GALLIUM (1L iNHL) - US
- **Hemophilia**: Hemlibra (Inh. patients) - US / positive CHMP opinion
- **Multiple Sclerosis**: Ocrevus – US / EU
- **Lung Cancer**: Alecensa – US / EU

Major trial read outs:

- **Hematology**: Venclexta: MURANO (R/R CLL); Polatuzumab: (R/R aNHL)
- **Lung Cancer**: Tecentriq IMpower150,
- **Renal Cancer**: Tecentriq IMmotion151

Breakthrough designations: Accelerating cycle times and reflecting the quality of our research

19 *Breakthrough Therapy Designations*

Year	Molecule
2018	***Balovaptan*** *(autism spectrum disorders)*
2017	***Polatuzumab vedotin + BR*** *(R/R DLBCL)*
	Venclexta + LDAC *(1L unfit AML)*
	Zelboraf *(BRAF-mutated ECD)*
	Rituxan *(Pemphigus vulgaris)*
2016	***Actemra*** *(Giant cell arteritis)*
	Alecensa *(1L ALK+ NSCLC)*
	Ocrevus *(PPMS)*
	Venclexta + HMA *(1L unfit AML)*
	Venclexta + Rituxan *(R/R CLL)*
2015	***Actemra*** *(Systemic sclerosis)*
	Tecentriq *(NSCLC)*
	Venclexta *(R/R CLL 17p del)*
	Hemlibra *(Hemophilia A inhibitors)*
2014	***Esbriet*** *(IPF)*
	Lucentis *(Diabetic retinopathy)*
	Tecentriq *(Bladder)*
2013	***Alecensa*** *(2L ALK+ NSCLC)*
	Gazyva *(1L CLL)*



2017: Strong Core results and significant operating free cash flow

Operating profit



EPS



Operating free cash flow



CER=Constant Exchange Rates

2017: 31st consecutive annual dividend increase



Payout ratio calculated as dividend per share divided by Core earnings per share (diluted); 2017 dividend as proposed by the Board of Directors;
Note: For 1995, a special dividend was paid out to mark F. Hoffmann-La Roche's 100th anniversary in 1996

2017 performance

Outlook

Record number of pipeline assets at pivotal stage



2018 outlook

Group sales growth[1]	• Stable to low-single digit
Core EPS growth[1]	• Broadly in line with sales, excl. US tax reform benefit • High-single digit, incl. US tax reform benefit
Dividend outlook	• Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER)

Pharmaceuticals Division

Daniel O'Day
CEO Roche Pharmaceuticals

2017 results

Innovation

Outlook

2017: Pharma Division sales

Strong growth in US due to ongoing launches

	2017 CHFm	2016 CHFm	Change in % CHF	Change in % CER
Pharmaceuticals Division	**41,220**	**39,103**	**5**	**5**
United States	20,496	18,594	10	10
Europe	9,051	9,159	-1	-2
Japan	3,713	3,711	0	3
International	7,960	7,639	4	4

CER=Constant Exchange Rates

2017: Pharma Division

Core operating profit growth broadly in line with sales, supporting new launches

	2017 CHFm	2017 % sales
Sales	**41,220**	**100.0**
Royalties & other op. inc.	2,284	5.5
Cost of sales	-8,707	-21.1
M & D	-6,720	-16.3
R & D	-9,036	-21.9
G & A	-1,440	-3.5
Core operating profit	**17,601**	**42.7**

2017 vs. 2016
CER growth



+4% in CHF

CER=Constant Exchange Rates

2017: Strong sales performance with increasing contribution from new launches



Absolute values and growth rates at Constant Exchange Rates (CER)

2017: Oncology portfolio rejuvenation ongoing



- Perjeta: Strong growth in all regions; Early APHINITY approval in the US achieved
- Kadcyla: Growth driven by International, US, and EU

- EU: Decline due to breast cancer reimbursement in France
- US: Lung cancer shares stabilizing after CIT entry in May

- US: Gazyva 1L FL approval achieved (priority review); key centers started adoption
- EU: Good initial uptake of Gazyva in 1L FL in the early launch countries

- Increased competition

- US: Stable 2L lung cancer share; Increasing 1L cisplatin ineligible bladder share
- EU: Launch in lung (2/3L) and bladder (2L and 1L cisplatin ineligible) ongoing

- US: 2L market share approaching 70%
- US/EU: Early 1L approvals achieved; FDA approval for the FMI FoundationOne assay

- EU: Increasing competition from CIT

FY 2017 Oncology sales: CHF 25.7bn (CER growth +3%); All growth rates at Constant Exchange Rates (CER); CIT=cancer immunotherapy; FL=follicular lymphoma; FMI=Foundation Medicine

HER2 franchise: Growth driven by all products



HER2 franchise Q4 2017

- Perjeta (+22%): Strong demand in neoadj. and 1L mBC driven by all regions; Accelerated growth in the US following approval in adjuvant BC (APHINITY)
- Kadcyla (+12%): Growth in International, US and EU

Outlook 2018

- US: Uptake of Perjeta + Herceptin in eBC following early APHINITY approval
- EU: Approval of APHINITY
- EU: Market entry of Herceptin biosimilars

CER=Constant Exchange Rates

CD20 franchise: Entering the transition phase in hematology



CD20 franchise Q4 2017

- MabThera/Rituxan (onc) US (+3%): Volume growth in all indications
- MabThera/Rituxan (onc) EU (-25%): Biosimilar launch in EU5 done; additional launches in smaller countries ongoing
- Gazyva/Gazyvaro (+42%): Positive early launch signals after 1L FL approvals in EU and US

Outlook 2018

- Overall CD20 franchise decline due to biosimilar erosion
- US/EU approval of Venclexta+Rituxan in R/R CLL (MURANO)

CER=Constant Exchange Rates; FL=follicular lymphoma; CLL=chronic lymphoid leukemia

Immunology: Annualized sales of around CHF 8bn



Immunology Q4 2017

Esbriet (+17%)

- Penetration in mild and moderate patient segment increasing, but slower than expected

Xolair (+15%)

- Asthma: US pediatrics launch ongoing; only biologic approved for children

Actemra (+14%)

- Launch in giant cell arteritis ongoing
- Further increase in SC uptake

Outlook 2018

- Further strong growth expected with exception of MabThera/Rituxan

CER=Constant Exchange Rates; SC=subcutaneous

Ocrevus: >5% US market share after three quarters



Ocrevus Q4 2017

- First patients returned for second treatment
- Continued strong uptake in RMS and PPMS (60/40)
- RMS: 30% treatment naive/previously discontinued vs. 70% switches from all other approved medications
- Broad base of prescribers and further increased level of US insurance coverage

Outlook 2018

- Further increasing US market share with earlier use across both indications
- EU approval achieved with label in RMS and PPMS

RMS=relapsing forms of multiple sclerosis; PPMS=primary progressive multiple sclerosis

2017 results

Innovation

Outlook

2017: Key late-stage news flow

	Compound	Indication	Milestone	
Regulatory	**Alecensa**	2L ALK+ NSCLC	EU approval	✓
	Ocrevus	RMS / PPMS	US/EU launch	✓
	Tecentriq	1L cisplatin ineligible mUBC	US approval	✓
	Tecentriq	2/3L NSCLC and 1/2L mUBC	EU approval	✓
	Gazyva	1L FL (iNHL)	US/EU filing	✓
	Actemra	Giant cell arteritis	US/EU approval	✓
	Hemlibra	Hemophilia A inhibitors	US/EU filing	✓
Phase III readouts	**Perjeta + Herceptin**	Adjuvant HER2+ BC	Ph III APHINITY	✓
	Alecensa	1L ALK+ NSCLC	Ph III ALEX	✓
	Venclexta + Rituxan	R/R CLL	Ph III MURANO	✓
	Tecentriq + chemo/ Tecentriq + chemo + Avastin	1L NSCLC	Ph III IMpower150	✓
	lampalizumab	Geographic atrophy	Ph III SPECTRI/CHROMA	✗
	Hemlibra	Hemophilia A non-inhibitors	Ph III HAVEN 3	✓

Additional 2017 news flow:

- **Lucentis**: US approval in mCNV and diabetic retinopathy
- **Rituxan Hycela**: US approval for blood cancers
- **Hemlibra**: Positive Ph III interim results in pediatric inhibitors (HAVEN 2) and positive Ph III interim results in inhibitors/non-inhibitors every 4 weeks dosing (HAVEN 4)
- **Gazyva**: EU/US approval in 1L FL
- **Alecensa**: US/EU approval in 1L ALK+ NSCLC
- **Perjeta + Herceptin**: Early US approval in adjuvant HER2+ eBC (APHINITY)
- **Hemlibra**: Early US approval in inhibitors
- **Tecentriq + Avastin**: Positive Ph III results in 1L RCC (IMmotion151)

2017: Key new launches with annualized sales of >CHF 7bn





Update late-stage oncology pipeline

Lung: NSCLC, SCLC, ALK+NSCLC

2/3L	Tecentriq	**OAK**	✓
1L non-sq	Tecentriq+carbo/pac+/-Avastin	**IMpower150**	✓
1L non-sq	Tecentriq+carbo+nab-pac	**IMpower130**	
1L sq	Tecentriq+carbo+pac/nab-pac	**IMpower131**	
1L non-sq	Tecentriq+cis/carbo+pem	**IMpower132**	
1L Dx+	Tecentriq	**IMpower110**	
Adj	Tecentriq	**IMpower010**	
1L SCLC	Tecentriq+carbo+etoposide	**IMpower133**	
1L ALK+	Alecensa	**ALEX; J-ALEX**	✓

Melanoma

1L BRAFwt	Tecentriq+Cotellic	**IMspire170**
1L BRAFmut	Tecentriq+Cotellic+Zelboraf	**IMspire150 TRILOGY**

Renal

1L	Tecentriq+Avastin	**IMmotion151**	✓
Adj	Tecentriq	**IMmotion010**	

Bladder

1L/2L+	Tecentriq	**IMvigor210 C2**	✓
1L	Tecentriq	**IMvigor210 C1**	✓
2L+	Tecentriq	**IMvigor211**	✗
1L	Tecentriq+/-gem/plat	**IMvigor130**	
Adj MIBC	Tecentriq	**IMvigor010**	



✓ = **approved or positive read-out**

Breast: TNBC; HER2+; ER+/HER2-

1L TNBC	Tecentriq+nab-pac	**IMpassion130**	
1L TNBC	Tecentriq+pac	**IMpassion131**	
Neoadj TNBC	Tecentriq+nab-pac	**IMpassion031**	
Adj HER2+	Perjeta+Herceptin	**APHINITY**	✓
ER+/HER2-	taselisib+fulvestrant	**SANDPIPER**	
1L Dx+ TNBC	ipatasertib+paclitaxel	**IPATunity130 C1**	
1L Dx+ HR+ mBC	ipatasertib+paclitaxel	**IPATunity130 C2**	

Colorectal

3L	Tecentriq+Cotellic	**IMblaze370**

Ovarian

Front-line	Avastin/carbo/pac+/-Tecentriq	**IMaGYN050**

Prostate

1L CRPC	ipatasertib+abiraterone	**IPATENTIAL150**
2/3L CRPC	Tecentriq+enzalutamide	**IMbassador250**

Hematology: CLL, MM, AML

1L CLL	Venclexta*+Gazyva	**CLL14**	
R/R CLL	Venclexta*+Rituxan	**MURANO**	✓
R/R MM	Venclexta*+bortezomib/dexa	**BELLINI**	
R/R AML	idasanutlin+cytarabine	**MIRROS**	
1L AML	Venclexta*+azacitidine	**Viale-A**	
1L DLBCL	Polatuzumab+Rituxan-CHP	**POLARIX**	

tba=to be announced; carbo=carboplatin; pac=paclitaxel; nab-pac=nab-paclitaxel (Abraxane); cis=cisplatin; pem=pemetrexed; gem=gemcitabine; plat=platinum; dexa=dexamethasone; *Venclexta in collaboration with AbbVie

CIT 1L lung cancer program reading out in H1 2018

Addressing all market segments

IMpower133[1]
(Tecentriq+cb+etoposide)
PFS/OS

IMpower131
(Tecentriq+cb+pac/nab-pac)
PFS/OS



IMpower150
(Tecentriq+cb/pac+/-Avastin) ✔ (PFS)
PFS/OS (H1 2018)

IMpower130
(Tecentriq+cb+nab-pac)
PFS/OS

IMpower132
(Tecentriq+cp/cb+pem)
PFS/OS

= Roche first-to-market with chemo combo

Tecentriq has the potential to be first-to-market chemo combo in 1L SCLC and 1L squamous NSCLC (45% of the total market)

Source: Datamonitor; incidence rates 7 major markets (US, Japan, France, Germany, Italy, Spain, UK); Note: Outcome studies are event driven, timelines may change; [1]IMpower133 in extensive stage SCLC; CIT=cancer immunotherapy; cb=carboplatin; pac=paclitaxel; nab-pac=nab-paclitaxel (Abraxane); cp=cisplatin; pem=pemetrexed

Tecentriq in 1L NSCLC

Positive interim results presented at ESMO IO

Ph III interim results (IMpower150)

	E4599[1]	IMpower150[2]	
	Avastin+cb/pac vs cb/pac	Tecentriq+Avastin+cb/pac vs Avastin+cb/pac (Arm B vs C)	
Patient population	1L AC	1L ITT-WT	1L T_{eff}-high WT
Patient number	N=878	N=692	N=284
ORR	35% vs. 15%	64% vs 48%	69% vs 54%
mOS (mos)	12.3 vs. 10.3 HR 0.79, p=0.003	19.2 vs 14.4 HR 0.775*, p=0.0262	--
mPFS (mos)	6.2 vs. 4.5 HR 0.66, p<0.001	8.3 vs 6.8 HR 0.617, p<0.0001	11.3 vs 6.8 HR 0.505, p<0.0001
Landmark PFS @ 1yr	18% vs 8.5%**	37% vs 18%	46% vs 18%

- Statistically significant and clinically meaningful PFS improvement
- OS has numerical improvement in Arm B vs C, but data are not fully matured. Next interim analysis for all arms in 1H 2018.

PFS Subgroup analysis



- PFS benefit (Arm B vs C) in key subgroups including patients with EGFR+ and ALK+ mutations, Teff low signatures, PDL1-negative tumors and liver metastases

[1] Sandler A, et al., NEJM 2006; [2] Reck M, et al., ESMO IO 2017; *OS data preliminary. Mature OS expected in H1 2018; **taken from KM curve; cb=carboplatin; pac=paclitaxel; AC=all-comers; ITT=intent-to-treat; WT=wild type; ORR=overall response rate; mOS=median overall survival; mPFS=median progression free survival; TC=tumor cells; IC=immune cells

Late-stage hematology: Improving the standard of care and extending into new indications

American Society of Hematology
Helping hematologists conquer blood diseases worldwide
Atlanta, Dec 8-12

Incidence rates (330,000 pts[1])



[1] Datamonitor; incidence rates includes the 7 major markets (US, Japan, France, Germany, Italy, Spain, UK); CLL=chronic lymphoid leukemia; DLBCL (aNHL)=diffuse large B-cell lymphoma; iNHL=indolent non-hodgkin`s lymphoma; AML=acute myeloid leukemia; MM=multiple myeloma; MDS=myelodysplastic syndrome; ALL=acute lymphoblastic leukemia; Venclexta in collaboration with AbbVie; Gazyva in collaboration with Biogen; Polatuzumab vedotin in collaboration with Seattle Genetics

Polatuzumab vedotin and Venclexta
Shifting the standard of care in DLBCL and CLL

American Society of Hematology
Helping hematologists conquer blood diseases worldwide
Atlanta, Dec 8-12

Polatuzumab vedotin[1]
Phase II (GO29365) update in R/R DLBCL

Pola + bendamustine/Rituxan vs bendamustine/Rituxan

EMA PRIME
FDA BTD



- Ph III study (POLARIX): Polatuzumab vedotin + Rituxan-CHP in 1L DLBCL achieved first-patient-in
- Polatuzumab vedotin could become potential foundational component in all regimes treating B-cell malignancies

Venclexta[2]
Phase III (MURANO) interim results in R/R CLL

Venclexta + Rituxan vs bendamustine/Rituxan

FDA BTD



- MURANO data filed in US and EU
- Ongoing Ph III studies in 1L CLL (CLL14), 1L AML (Viale-A and Viale-C) and R/R MM (BELLINI)
- Potential early filing in 1L AML based on Ph1/2 results (with BTD)*

[1] Sehn L. H. *et al.*, ASH 2017; [2] Seymour J. *et al.*, ASH 2017; DLBCL=diffuse large B-cell lymphoma; CLL=chronic lymphoid leukemia; AML=acute myeloid leukemia; NHL=non-hodgkin`s lymphoma; MM=multiple myeloma; *as announced by partner AbbVie; Polatuzumab vedotin in collaboration with Seattle Genetics; Venclexta in collaboration with AbbVie

Hemlibra`s Ph III development nearing completion

HAVEN 1, 2 updates and HAVEN 4 run-in presented at ASH



- ✓ US approval in Q4
  EU positive CHMP opinion
- ✓ US approval in Q4
  EU positive CHMP opinion
- ✓ Positive results announced
- ✓ Positive interim results announced

Hemlibra for inhibitor patients

Inhibitor results keep improving over time

American Society of Hematology
Helping hematologists conquer blood diseases worldwide
Atlanta, Dec 8-12

Roche

Phase III update in adult inhibitors (HAVEN 1)





- HAVEN 1 results improved further over time
- 88% treated bleed reduction in the intra-patient analysis
- Share of patients with zero bleeds increased to 88% in weeks 49-72

Phase III update in pediatric inhibitors (HAVEN 2)

	% zero bleeds (95% CI) N=57*	% zero bleeds (95% CI) N=23**	ABR*** (95% CI) N=23**	Median ABR (IQR) N=23**
Treated bleeds	**94.7** (85.4; 98.9)	**87.0** (66.4; 97.2)	**0.2** (0.06; 0.62)	**0.0** (0.00; 0.00)
All bleeds	**64.9** (51.1; 77.1)	**34.8** (16.4; 57.3)	**2.9** (1.75; 4.94)	**1.5** (0.00; 4.53)
Treated spontaneous bleeds	**98.2** (90.6; 100.0)	**95.7** (78.1; 99.9)	**0.1** (0.01; 0.47)	**0.0** (0.00; 0.00)
Treated joint bleeds	**98.2** (90.6; 100.0)	**95.7** (78.1; 99.9)	**0.1** (0.01; 0.47)	**0.0** (0.00; 0.00)

- 40 additional patients and ~ 6 months of additional follow-up confirm earlier analysis
- 94.7% of children on Hemlibra prophylaxis with zero treated bleeds

Mancuso M.E. *et al.,* ASH 2017; Young G. et al., ASH 2017; ABR=Annualized Bleeding Rate, BPA=Bypassing agent; IQR=interquartile range; *Aged <12 years; **Primary efficacy results (ABR analysis) based only on patients aged < 12 yrs on study for ≥12 wks; ***Negative binomial regression model

Anti-VEGF/Ang2 biMAb in DME

Ph II results (BOULEVARD) to be presented

IR conference call February 13

Angiogenesis, Exudation, and Degeneration 2018
February 10, 2018
Miami, FL

Anti-VEGF/Ang2 biMAb



- First bispecific antibody in ophthalmology binding to VEGF and Angiopoetin2 (Ang2)
- Engineered Fc for improved pharmacokinetics and faster systemic clearance

Scientific rationale in DME



- Characteristic DME pathology is retinal microvascular inflammation, ischemia, and breakdown of the blood-retinal barrier, resulting in leakage of fluid into the retina and vision loss
- Ang2 inhibition could improve blood-retinal barrier stability and reduce retinal vascular inflammation, contributing to an improved therapeutic benefit

DME=diabetic macular edema

Autism: V1a receptor antagonist (balovaptan)

Early data from first Ph II study in adults

FDA BTD

V1a receptor antagonist



- Vasopressin (V)1a receptor modulates social behavior and is implicated in ASD
- Efficacy observed in environmental and genetic rodent models of autism
- Orally available, selective V1a receptor antagonist
- Good pharmacokinetic profile and well tolerated in Ph I and II studies

Phase II (VANILLA) results:



- Primary EP (SRS-2) not met; however main secondary EP (Vineland™-II) met
- Vineland™-II selected and agreed upon with health authorities as primary endpoint in future studies

Bolognani F. et al., IMFAR 2017; ASD=autism spectrum disorder; SRS-2=social responsiveness scale-2; Vineland™-II=Vineland Adaptive Behavior Scale 2nd Edition

Ignyta`s entrectinib (pan-TRK/ROS1 inhibitor) fits our strategy*

Targeting mutations across different solid tumor types

EMA PRIME

FDA BTD

Identify patients with targeted mutations



FOUNDATIONONE™

FOUNDATION MEDICINE®

Roche Diagnostics

Entrectinib: Treat selected patients across different tumors



FoundationOne & Roche Diagnostics support identification of rare tumor mutations

[1] NTRK 1,2,3=Neurotropic Tropomyosin Receptor Kinase 1, 2, 3; ROS1=c-ros oncogene 1

[2] US+EU5 Prevalence: ROS1 in solid tumors ~6000 patients and NTRK in solid tumors ~8000 patients (both mutations have prevalence of 0.5 – 1.5% in most solid tumors; 80% in MASC)

* The acquisition of Ignyta Inc. by Roche Holdings Inc. is pending and is subject to customary closing conditions. The closing of the transaction is expected to take place in the first half of 2018.

2017 results

Innovation

Outlook

2018: Key late-stage news flow*

	Compound	Indication	Milestone
Regulatory	**Ocrevus**	RMS / PPMS	EU approval ✓
	Perjeta + Herceptin	Adjuvant HER2+ eBC	EU approval
	Tecentriq + cb/pac +/- Avastin	1L non-sq NSCLC	US/EU filing
	Tecentriq + Avastin	1L RCC	US/EU filing
	Hemlibra	Hemophilia A inhibitors	EU approval
	Hemlibra	Hemophilia A non-inhibitors	US/EU filing
	Hemlibra	Every 4 weeks dosing inhibitors/non-inhibitors	US/EU filing
	baloxavir marboxil (CAP endonuclease inhibitor)	Influenza	US filing initiation
	Venclexta + Rituxan	R/R CLL	US/EU approval
Phase III readouts	**Tecentriq + chemo**	1L lung program	Ph III IMpower130/131/132/133
	Tecentriq + nab-pac	1L TNBC	Ph III IMpassion130
	Tecentriq + Cotellic	2/3L CRC	Ph III IMblaze370 / COTEZO
	Actemra	Systemic sclerosis	Ph III focuSSced

* Outcome studies are event-driven: timelines may change

Diagnostics Division

Roland Diggelmann
CEO Roche Diagnostics

2017: Diagnostics Division sales

Growth driven by CPS & Tissue Diagnostics

	2017 CHFm	2016 CHFm	Change in % CHF	Change in % CER
Diagnostics Division	**12,079**	**11,473**	**5**	**5**
Centralised and Point of Care Solutions	7,179	6,698	7	7
Diabetes Care	1,965	2,016	-3	-4
Molecular Diagnostics	1,920	1,845	4	4
Tissue Diagnostics	1,015	914	11	11

CER=Constant Exchange Rates
Underlying growth of Molecular Diagnostics excluding sequencing business: +4%

2017: Diagnostics Division regional sales

Strong growth in emerging markets



+17% growth in E7 countries[2]

[1] Europe, Middle East and Africa; [2] Brazil, China, India, Mexico, Russia, South Korea, Turkey
All growth rates at Constant Exchange Rates

2017: Diagnostics Division highlights
Growth driven by Immunodiagnostics



- Driven by immunodiagnostics (+13%); clinical chemistry (+3%)
- Continued US pricing and reimbursement pressures
- Virology (0%), HPV (+15%); MD Sys (+10%)
- Advanced staining portfolio (+11%); primary staining (+12%) and companion diagnostics (+13%)

[1] Underlying growth of Molecular Diagnostics excluding sequencing business: +4%
CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa

2017: Diagnostics Division

Core operating profit growth excl. PSI +4%

	2017 CHFm	2017 % sales
Sales	**12,079**	**100.0**
Royalties & other op. inc.	163	1.3
Cost of sales	-5,659	-46.8
M & D	-2,792	-23.1
R & D	-1,356	-11.2
G & A	-526	-4.4
Core operating profit	**1,909**	**15.8**

2017 vs. 2016
CER growth



-1% in CHF

CER=Constant Exchange Rates; PSI=Past Service Income 2016

Implementing the fully integrated core laboratory

Connecting disciplines
(cobas 6800/8800, cobas 6500, cobas p 612)

Highest throughput analysers
(cobas e 801, cobas c 702)



Comprehensive menu
(Procalcitonin; Zika; MPX; Syphilis)

Digitalised data management (Navify tumor board)

Seamless workflow and laboratory IT
(CCM High Speed)

Immunodiagnostics: 32% of sales, growing +13%

Strong uptake and market expansion of cobas e 801

Launch Excellence

- June 16: launch in CE mark countries
- Apr 17: US launch
- Complete menu of 96 parameters available in CE mark countries

Units since launch ~900*



*Actual installed capacity base since launch June 2016

Launch of cobas t 511 / t 711

First cassette-based laboratory coagulation analysers

cobas t 711 analyser*

- First customer monitoring with 10 assays
- Automatization reduces errors and increases walkaway capacity
- Maximized test capacity (up to 34200 tests on board)

*__cobas t__ 711 analyser is anticipated to be fully integrated into the SWA workflow by Q4 2018

Acquisition of Viewics, Inc.

Data-driven business analytics and digital capabilities for the laboratory

- Complements and expands our portfolio with business analytics
- Supports our customers in improving their lab performance and processes
- Proprietary big data extraction and cleansing integration technology
- HIPAA* certified massively scalable platform

*HIPPA: Health Insurance Portability and Accountability Act

Bridging advanced analytics to provide clinical decision support solutions for patients and physicians

In-vitro data

Roche

Biomarkers
Tissue pathology
Genomics & sequencing

Digital platform & analytics

Combined patient records
Real-time data
Best practices
Research outcomes

Workflow solutions + apps
Speed, accuracy, confidence

Clinical decision support
Speed, accuracy, confidence

Data driven patient care
Early diagnosis
Early intervention
Individualised treatment

In-vivo data

Medical imaging
Patient monitoring

Combine in-vitro and in-vivo expertise – complementary strategic partnership

Key launches 2017: All targets achieved

	Area	Product	Market
Instruments/ Devices	**Central Laboratory**	cobas 8000 <e 801> – High throughput immunochemistry analyser CCM High Speed – cobas connection module (CCM) for up to 6000 samples/hour	US ✓ WW ✓
	Coagulation Testing	cobas t 511 / t 711 – Medium and high volume coagulation systems	EU ✓
	Point of Care	CoaguChek Vantus – Hand-held coagulation monitoring system for Patient Self-Testing	US ✓
	Diabetes Care	Accu-Chek Instant bG System – Effortless, accurate and affordable bG system for price sensitive markets	EU ✓
Tests/ Assays	**HPV**	cobas HPV – Next generation HPV DNA test leveraging 68/8800 Automation to detect 14 hrHPV with simultaneous detection of genotypes 16 and 18 CINtec Histology – Diagnostic component of the Roche Cervical Cancer portfolio	EU ✓ US ✓
	Virology	cobas HIV 1&2 Qual – For use on the cobas 6800/8800 Systems; for diagnosis of acute HIV 1 or 2 infection and for confirmation of HIV 1 or 2 infection	EU ✓
	Sequencing	AVENIO ctDNA panels - Liquid biopsy for circulating tumor DNA, 3 panels: targeted panel (17 genes for cancer therapy selection), expanded panel (77 genes for cancer therapy selection), surveillance panel (197 genes)	EU/US ✓
	cobas Liat	cobas Liat C.diff – Qualitative IVD test, that utilizes real-time PCR, for the direct detection of the tcdB gene of toxigenic *C. difficile* in unformed stool specimens	EU ✓
		cobas Liat MRSA/SA – Qualitative IVD test, that utilizes real-time PCR, for the direct detection of MRSA and *Staphylococcus aureus* DNA from nasal swabs	EU ✓
	Women's Health	AMH – Immunoassay for the in vitro quantitative determination of anti-Mullerian hormone (AMH) in human serum and plasma for the assessment of the ovarian reserve in women presenting to fertility clinics	US ✓
	Companion Diagnostics	PD-L1 (SP142) for Bladder Cancer* – complementary diagnostic for Tecentriq	EU ✓
		PD-L1 (SP142) for NSCLC* – complementary diagnostic for Tecentriq	EU ✓

* = Achieve commercial readiness, dependent on Pharma label and approval

Key launches 2018

	Area	Product	Market
Instruments/ Devices	**Central Laboratory**	cobas pro integrated solution – Serum Work Area solution for medium throughput to lower high throughout labs	CE
	Specialty Testing	cobas m 511 – World's first fully digital morphology analyzer and cell counter	US
	Workflow	CCM connectivity to cobas c513 – Connection of cobas c 513 to CCM Automation System for high volume HbA1c testing	WW
	Tissue Dx	BenchMark ULTRA Plus – New and differentiated Advanced Staining System	CE
	Digital Pathology	VENTANA DP200 – Reliable low-volume scanner with superior image quality	CE
	Diabetes Care	Solo Patch Pump – Small and tubeless insulin delivery device operated through a remote control which includes a blood glucose meter	CE
Tests/ Assays	**Endocrinology**	IGFBP3 – Completion of the existing growth hormone menu of hGH and IGF-1	CE
	Infectious Diseases	Zika IgG – Highly specific immunoassay for the in vitro qualitative detection of IgG antibodies to Zika virus in human serum and plasma	CE
	Microbiology	cobas CT/NG – Highest throughput CT/NG test on the market with workflow efficiency benefits	US
		cobas 6800/8800 MTB/MAI – High volume solution for MTB/MAI testing; efficient approach to disease management (mixed testing) for infectious disease	CE
	Virology	Plasma Separation Card – Card-like sample collection device; separates plasma from whole blood; for use with CAP/CTM HIV-1 & cobas HIV-1 (6800/8800)	CE ✔
	Sequencing	AVENIO FFPET RUO oncology kits – 3 separate tissue based assay kits for solid tumors	WW
Software	**Decision Support**	NAVIFY Tumor Board v 1.x – EMR integration	WW

Finance

Alan Hippe
Chief Financial Officer

2017 results

Focus on Cash

Outlook

FY 2017: Highlights

Business

- Good sales growth of +5%[1] and Core operating profit up +3%[1]
- Core EPS growth +5%[1]
- Dividend in Swiss francs further increased

Cash flow

- Significant cash generation (Operating Free Cash Flow of CHF 17.8bn, +26%[1])
- Net debt lower by CHF 6.3bn vs. YE 2016 as Free Cash Flow of CHF 13.4bn more than offsets dividends paid

Net financial results

- Core net financial result improved by +25%[1] driven mainly by 15%[1] lower interest expenses[2] and lower losses on debt redemption

IFRS

- Net income -9%[1] due to impairment of intangible assets

[1] At Constant Exchange Rates (CER)
[2] incl. amortisation of debt discount and net gains on interest rate derivatives

2017: Group performance

Core EPS growth +5%, in line with sales growth

	2017 CHFm	2016 CHFm	Change in % CHF	Change in % CER
Sales	**53,299**	**50,576**	**5**	**5**
Core operating profit	**19,012**	**18,420**	**3**	**3**
as % of sales	*35.7*	*36.4*		
Core net income	**13,404**	**12,688**	**6**	**6**
as % of sales	*25.1*	*25.1*		
Core EPS (CHF)	**15.34**	**14.53**	**6**	**5**
IFRS net income	**8,825**	**9,733**	**-9**	**-9**
Operating free cash flow	**17,827**	**14,086**	**27**	**26**
as % of sales	*33.4*	*27.9*		
Free cash flow	**13,420**	**9,130**	**47**	**47**
as % of sales	*25.2*	*18.1*		

CER=Constant Exchange Rates

2017: Group operating performance

Core operating profit growth +3%, supporting new launches

	2017 CHFm	2017 % sales
Sales	**53,299**	**100.0**
Royalties & other op. inc.	2,447	4.6
Cost of sales	-14,366	-27.0
M & D	-9,512	-17.8
R & D	-10,392	-19.5
G & A	-2,464	-4.6
Core operating profit	**19,012**	**35.7**

2017 vs. 2016
CER growth



+3% in CHF

CER=Constant Exchange Rates

2017: Core operating profit and margin



[1] At CER=Constant Exchange Rates

2017: Core net financial result

+25% improvement mainly due to lower interest expenses and lower losses on debt redemption



CER = Constant Exchange Rates (avg full year 2016)

[1] incl. amortisation of debt discount and net gains on interest rate derivatives

Core net financial result: Continuous improvement



	2015	2016	2017
Effective int. rate	*3.7%*	*2.9%*	*2.8%*

2017/18: Group Core tax rate



2018: Impact of US tax reform

- Corporate Core tax rate expected to be in the low twenties[1] vs mid to high-twenties range previously

[1] barring any changes to tax legislation or other one-off items

FY 2017: Non-core items; IFRS result impacted by impairments of goodwill & intangible assets

Full Year	2016	2017	CHFm	CHF	CER
Core operating profit	**18,420**	**19,012**	**+592**	**+3%**	**+3%**
Global restructuring plans	-1,233	-1,208	+25		
Amortisation of intangible assets	-1,783	-1,691	+92		
Impairment of intangible assets[1]	-1,508	-3,518	-2,010		
Alliances & Business Combinations	+234	+350	+116		
Legal & Environmental[2]	-61	+58	+119		
Total non-core operating items	-4,351	-6,009	-1,658		
IFRS operating profit	**14,069**	**13,003**	**-1,066**	**-8%**	**-8%**
Total financial result & taxes	-4,336	-4,178	+158		
IFRS net income	**9,733**	**8,825**	**-908**	**-9%**	**-9%**

CER=Constant Exchange Rates; [1] incl. goodwill [2] incl. pension plan settlements

2017 results

Focus on Cash

Outlook

2017: Strong operating free cash flow and margin



[1] At CER=Constant Exchange Rates

2017: Strong operating free cash flow

CHF +3.7bn/+26% higher than PY



CER = Constant Exchange Rates (avg full year 2016); OP=operating profit; NWC=net working capital; PP&E=property, plant & equipment; IA=intangible assets

2017: Group net debt significantly improved

Lower net debt due to improved free cash flow



CER = Constant Exchange Rates (avg full year 2016)

Balance sheet

Net debt to total assets now at 9% vs. 19% at YE 2015



Balance sheet 31 December 2017



CER = Constant Exchange Rates (avg full year 2016)

2017 results

Focus on Cash

Outlook

Low currency impact in 2017



In 2017 impact is (%p):

	Q1	HY	Sep YTD	FY
Sales	**0**	**0**	**0**	**0**
Core operating profit		**0**		**0**
Core EPS		**0**		**1**

***2018** currency impact[1] expected (based on **31 Dec 2017** FX rates):*

- Up to +1%p FX impact on Sales, Core OP & Core EPS

[1] On Group growth rates

2018 outlook

Group sales growth[1]	• Stable to low-single digit
Core EPS growth[1]	• Broadly in line with sales, excl. US tax reform benefit • High-single digit, incl. US tax reform benefit
Dividend outlook	• Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER)

Full Year 2017: Core EPS

Core EPS 2017 of CHF 15.45 is basis for outlook Core EPS growth 2018 at CER



CER=Constant Exchange Rates (avg full year 2017)

Pipeline summary

Changes to the development pipeline
FY 2017 update

New to phase I

6 NMEs:
RG6109 NME - AML
RG6151 NME - asthma
RG6171 SERD (3) – ER+ (HER2neg) mBC
RG6174 NME – inflammatory diseases
RG6264 Perjeta + Herceptin FDC SC – HER2+ eBC
RG7816 GABA-Aa5 PAM - autism

1 AIs:
RG7446 Tecentriq + tazemetostat – r/r DLBCL

New to phase II

1 NME:
RG1678 bitopertin – beta thalassemia

New to phase III

1 NMEs:
RG6152 baloxavir marboxil (CAP endonuclease inh) – influenza

6 AIs:
RG3648 Xolair – nasal polyps
RG7421 Cotellic + Tecentriq – 1L BRAF WT melanoma
RG7440 ipatasertib – 1L TNBC/HR+ BC
RG7446/RG7853 Tecentriq or Alecensa - 1L NSCLC Dx+
RG7596 polatuzumab vedotin -1L DLBCL
RG7601 Venclexta + LDAC – 1L AML

New to registration

1 AI following filing in US and EU:
RG7601 Venclexta + Rituxan – r/r CLL

2 AIs following filing in US:
RG435 Avastin – FL ovarian cancer
RG3645 Lucentis 0.3mg PFS – DME/DR

1 AI following filing in EU:
RG1569 Actemra auto injector – RA

Removed from phase I

3 NMEs:
RG6047 SERD (2) – ER+ (HER-neg) mBC
RG7203 PDE10A inh – schizophrenia
RG7986 ADC – r/r NHL

Removed from phase II

1 AI:
RG3502 Kadcyla + Tecentriq – 2L Her2+ mBC

Removed from phase III

1 NME:
RG7417 lampalizumab – geographic atrophy

Removed from registration

3 AIs following US approval:
RG435 Avastin - GBM
RG7159 Gazyva – 1L FL
RG7204 Zelboraf – Erdheim-Chester disease

1 AI following US and EU approval:
RG7853 Alecensa – 1L ALK+ NSCLC

1 NME following EU approval:
RG1594 Ocrevus - PPMS + RMS

Status as of February 1, 2018

Roche Group development pipeline

Phase I (43 NMEs + 23 AIs)

RG6264	Perjeta + Herceptin FDC SC	HER2+ BC
RG6026	CD20 TCB	heme tumors
RG6058	TIGIT ± Tecentriq	solid tumors
RG6109	--	AML
RG6114	mPI3K alpha inh	HR+ BC
RG6146	BET inh combos	solid + heme tumors
RG6160	-	multiple myeloma
RG6171	SERD (3)	ER+ (HER2neg) mBC
RG6180	personalized cancer vaccine ± T	oncology
RG6185	pan-RAF inh + Cotellic	solid tumors
RG7155	emactuzumab + Tecentriq	solid tumors
	emactuzumab + selicrelumab	solid tumors
RG7159	anti-CD20 combos	heme tumors
RG7386	FAP-DR5 biMAb	solid tumors
RG7421	Cotellic + Zelboraf + T	melanoma
	Cotellic + T	2L BRAF WT mM
RG7446	Tecentriq	solid tumors
	Tecentriq	NMIBC
	T-based Morpheus platform	solid tumors
	T + Avastin + Cotellic	2/3L CRC
	T ± Avastin ± chemo	HCC, GC, PaC
	T + Cotellic	solid tumors
	T + ipi/IFN	solid tumors
	T + Tarceva/Alecensa	NSCLC
	T + anti-CD20 combos	heme tumors
	T ± lenalidomide ± daratumumab	MM
	T + K/HP	HER2+ BC
	T + HMA	MDS
	T + radium 223	mCRPC
	T + guadecitabine	AML
	T + rucaparib	ovarian ca
	T + Gazyva/tazemetostat	r/r DLBCL + FL
RG7461	FAP IL2v FP combos	solid tumors
RG7601	Venclexta + Cotellic/idasanutlin	AML
	Venclexta ± azacitadine	r/r MDS
RG7741	ChK1 inh	solid tumors
RG7802	CEA TCB ± Tecentriq	solid tumors
RG7813	CEA IL2v FP* + Tecentriq	solid tumors
RG7828	CD20 TDB ± Tecentriq	heme tumors
RG7876	selicrelumab (CD40) + T	solid tumors
	selicrelumab + vanucizumab	solid tumors
RG7882	MUC16 ADC	ovarian ca
CHU	Raf/MEK dual inh	solid tumors
CHU	glypican-3/CD3 biMAb	solid tumors
RG6069	anti-fibrotic agent	fibrosis
RG6107	C5 inh MAb	PNH
RG6151	-	asthma
RG6174	-	inflammatory diseases
RG7835	IgG-IL2 FP	autoimmune diseases
RG7880	IL-22Fc	inflammatory diseases
RG7990	-	asthma
RG6004	HBV LNA	HBV
RG6080	nacubactam	bact. infections
RG7854	TLR7 agonist (3)	HBV
RG7861	anti-S. *aureus* TAC	infectious diseases
RG7907	HBV Capsid (2)	HBV
RG7992	FGFR1/KLB MAb	metabolic diseases
RG6000	-	ALS
RG6029	Nav1.7 inh (2)	pain
RG6042	ASO	Huntington's
RG7816	GABA Aa5 PAM	autism
RG7906	-	psychiatric disorders
RG6147	-	geographic atrophy
RG7945	-	glaucoma
CHU	PTH1 recep. ago	hypoparathyroidism
CHU	-	hyperphosphatemia

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

RG-No Roche/Genentech
CHU Chugai managed
PRO Proximagen managed
NOV Novimmune managed
*INN: cergutuzumab amunaleukin
**out-licensed to Galderma and Maruho for atopic dermatitis
*** Ph2 Pivotal
§ FPI expected Q1 2018
T=Tecentriq; TCB=T cell bispecific; TDB=T cell dependent bispecific

Phase II (19 NMEs + 9 AIs)

RG7388	idasanutlin §	polycythemia vera
RG7421	Cotellic + Tecentriq ± taxane	TNBC
RG7440	ipatasertib	TNBC neoadj
RG7596	polatuzumab vedotin	r/r DLBCL + FL
RG7601	Venclexta + Rituxan	DLBCL
	Venclexta + Rituxan	r/r FL
	Venclexta + azacitadine	1L MDS
RG7604	taselisib + letrozole	(HER2-neg) BC neoadj
RG7686	codrituzumab	liver cancer
RG3637	lebrikizumab ± Esbriet	IPF
RG6125	Cadherin-11 MAb	RA
RG6149	ST2 MAb	asthma
RG7159	obinutuzumab	lupus
RG7625	Cat-S antag	autoimmune diseases
RG7845	BTK inh	RA, lupus, CSU
CHU	nemolizumab**	pruritus in dialysis patients
PRO	VAP-1 inh	inflammatory disease
NOV	TLR4 MAb	autoimmune diseases
CHU	URAT1 inh	gout
RG1662	basmisanil	CIAS
RG1678	bitopertin	beta thalassemia
RG6083	olesoxime	SMA
RG6100	Tau MAb	Alzheimer's
RG7314	balovaptan (V1a receptor antag)	autism
RG7916	SMN2 splicer(2)***	SMA
RG7935	α-synuclein MAb	Parkinson's
RG3645	ranibizumab PDS	wAMD
RG7716	VEGF-ANG2 biMAb	wAMD, DME

Status as of February 1, 2018

Roche Group development pipeline

Phase III (9 NMEs + 34 AIs)

RG3502	Kadcyla	HER2+ BC adj
	Kadcyla + Perjeta	HER2+ BC adj
RG6013	Hemlibra	hemophilia A w/o FVIII inh
	Hemlibra	Q4W hemophilia A
RG7388	idasanutlin + chemo	AML
RG7440	ipatasertib + chemo	1L CRPC
	ipatasertib	1L TNBC/HR+ BC
RG7421	Cotellic + Zelboraf + T	1L BRAFm melanoma
	Cotellic + T	1L BRAF WT melanoma
RG7596	polatuzumab vedotin	1L DLBCL
RG7446	Tecentriq	NSCLC adj
	Tecentriq	MIBC adj
	Tecentriq Dx+	1L sq + non-sq SCLC
	Tecentriq	RCC adj
	T + nab-paclitaxel	1L non-sq NSCLC
	T + chemo+ Avastin	1L ovarian cancer
	T + chemo + Avastin	1L non-sq NSCLC
	T + chemo + pemetrexed	1L non-sq NSCLC
	T + nab-paclitaxel	1L sq NSCLC
	T + paclitaxel	1L TNBC
	T + nab-paclitaxel	1L TNBC
	T + nab-paclitaxel	TNBC neoadj
	T + Avastin	RCC
	T + Cotellic	3L CRC
	T ± chemo	1L mUC
	T + chemo	1L extensive stage SCLC
	T + enzalutamide	CRPC
RG7446/RG7853	Tecentriq or Alecensa	1L NSCLC Dx+
RG7601	Venclexta + Gazyva	1L CLL
	Venclexta + bortezomib	MM
	Venclexta + azacitidine	1L AML
	Venclexta + LDAC	1L AML
RG7604	taselisib + fulvestrant	ER+(HER2-neg) mBC
RG105	MabThera	pemphigus vulgaris
RG1569	Actemra	systemic sclerosis
RG3648	Xolair	nasal polyps
RG7413	etrolizumab	ulcerative colitis
	etrolizumab	Crohn's
RG6152	baloxavir marboxil (CAP endonuclease inh)	influenza
RG1450	gantenerumab	Alzheimer's
RG6168	satralizumab (IL-6R Mab)	NMO
RG6206	anti-myostatin adnectin	DMD
RG7412	crenezumab	Alzheimer's

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

RG-No Roche/Genentech
CHU Chugai managed
RG1569 Branded as RoActemra (EU)

T=Tecentriq

Registration (1 NME + 5 AIs)

RG435	Avastin[1]	ovarian FL
RG1273	Perjeta + Herceptin[2]	HER2+ BC adj
RG6013	Hemlibra[3]	hemophilia A FVIII inh
RG7601	Venclexta + Rituxan	r/r CLL
RG1569	Actemra auto injector[4]	RA
RG3645	Lucentis 0.3mg PFS[1]	DME/DR

1 US only
2 Approved in US
3 Approved in US; positive CHMP opinion
4 EU only

Status as of February 1, 2018

NME submissions and their additional indications

Projects currently in phase II and III



✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

Status as of February 1, 2018

AI submissions for existing products

Projects currently in phase II and III

2017

RG36452	**Lucentis 0.3mg PFS (US) ✓** DME/DR
RG1569	**Actemra auto injector (EU) ✓** RA
RG435	**Avastin (US) ✓** GBM
RG435	**Avastin (US) ✓** ovarian FL
RG1273	**Perjeta + Herceptin ✓** HER2+ BC adj.
RG7159	**Gazyva (US) ✓** 1L FL
RG7204	**Zelboraf (US) ✓** Erdheim-Chester disease
RG7601	**Venclexta + Rituxan (US) ✓** r/r CLL
RG7853	**Alecensa ✓** 1L ALK+ NSCLC

2018

RG105	**MabThera** pemphigus vulgaris
RG1569	**Actemra** systemic sclerosis
RG1569	**Actemra auto injector (US)** RA/GCA
RG7601	**Venclexta + Rituxan (EU) ✓** r/r CLL
RG7601	**Venclexta + azacitidine/LDAC** 1L AML
RG7446	**Tecentriq + Cotellic** 3L CRC
RG7446	**Tecentriq + chemo + Avastin** 1L non-sq NSCLC
RG7446	**Tecentriq + nab-paclitaxel** 1L sq NSCLC
RG7446	**Tecentriq + nab-paclitaxel** 1L non-sq NSCLC
RG7446	**Tecentriq + chemo + pemetrexed** 1L non-sq NSCLC
RG7446	**Tecentriq + chemo** 1L extens. stage SCLC
RG7446	**Tecentriq + Avastin** RCC
RG7446	**Tecentriq + nab-paclitaxel** TNBC

2019

RG7421	**Cotellic + Tecentriq** 1L BRAF WT melanoma
RG7421	**Cotellic + Tecentriq + Zelboraf** 1L BRAFmut melanoma
RG7446	**Tecentriq** 1L non-sq + sq NSCLC (Dx+)
RG7446	**Tecentriq + nab-paclitaxel** TNBC neoadj
RG7446	**Tecentriq + paclitaxel** 1L TNBC
RG7601	**Venclexta + Gazyva** 1L CLL
RG7601	**Venclexta + bortezomib** MM

2020 and beyond

RG3502	**Kadcyla + Perjeta** HER2+ BC adj.
RG3502	**Kadcyla** HER2+ BC adj.
RG7601	**Venclexta + Rituxan** r/r FL
RG7601	**Venclexta + Rituxan** DLBCL
RG7601	**Venclexta + aza** 1L MDS
RG7421	**Cotellic + Tecentriq ± taxane** TNBC
RG3645	**ranibizumab PDS** wAMD
RG3648	**Xolair** nasal polyps
RG7159	**obinutuzumab** lupus nephritis
RG7446/ RG7853	**Tecentriq or Alecensa** 1L NSCLC Dx+
RG7446	**Tecentriq ± chemo** 1L mUC
RG7446	**Tecentriq** NSCLC adj
RG7446	**Tecentriq** MIBC adj
RG7446	**Tecentriq + enzalutamide** CRPC
RG7446	**Tecentriq** RCC adj
RG7446	**Tecentriq + chemo + Avastin** 1L ovarian cancer

✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

Status as of February 1, 2018

Major granted and pending approvals 2017

Approved

US		EU		Japan-Chugai	
RG105	**Rituxan Hycela™** (SC) NHL/CLL, Jun 2017	RG435	**Avastin** chemo backbone extension rel. OC Pt-sensitive, Jun 2017	RG7446	**Tecentriq** 2L+ NSCLC, Jan 2017
RG435	**Avastin** GBM, Dec 2017	RG7159	**Gazyva** 1L follicular lymphoma, Sep 2017	CHU	**Actemra** Takayasu arteritis and giant cell arteritis, Aug 2017
RG1273	**Perjeta + Herceptin** HER2+ BC adj, Dec 2017	RG7446	**Tecentriq** mUC 2L, Sep 2017		
RG6013	**Hemlibra (emicizumab)** hemophilia A FVIII inh (ped + adults), Nov 2017	RG7446	**Tecentriq** 2L+ NSCLC, Sep 2017		
RG7159	**Gazyva** 1L follicular lymphoma , Nov 2017	RG7853	**Alecensa** 2L ALK+ NSCLC, Feb 2017 1L ALK+ NSCLC, Dec 2017		
RG7204	**Zelboraf** Erdheim-Chester disease, Nov 2017	RG1569	**Actemra** giant cell arteritis, Sep 2017		
RG7446	**Tecentriq** 1L bladder cancer, cis-ineligible, Apr 2017	RG1594	**Ocrevus** PPMS & RMS, Jan 2018		
RG7853	**Alecensa** 1L ALK+ NSCLC, Nov 2017				
RG1569	**Actemra** giant cell arteritis, May 2017 CRS, Aug 2017				
RG1594	**Ocrevus** PPMS & RMS, Mar 2017				
RG3645	**Lucentis** mCNV, Jan 2017 DR w/o DME, Apr 2017				

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

Pending Approval

RG435	**Avastin** Ovarian FL, Filed Aug 2017	RG1273	**Perjeta + Herceptin** HER2+ BC adj, Filed Aug 2017	RG6013	**emicizumab** hemophilia A FVIII inh (ped + adults), Filed Jul 2017
RG7601	**Venclexta + Rituxan** r/r CLL, Filed Dec 2017	RG6013	**Hemlibra (emicizumab)** hemophilia A FVIII inh (ped + adults), Filed Jun 2017		
RG3645	**Lucentis** 0.3 mg PFS DME/DR, Filed Dec 2017	RG7601	**Venclexta + Rituxan** r/r CLL, Filed Jan 2018		
		RG1569	**Actemra auto injector** RA, Filed Jan 2018		

Status as of February 1, 2018

Cancer immunotherapy pipeline overview

Phase I (10 NMEs + 28 AIs)

RG6026	CD20 TCB	hematopoietic tumors
RG6058	TIGIT ± Tecentriq	solid tumors
RG6160	-	multiple myeloma
RG6180	personalized cancer vaccine ± T	oncology
RG7155	emactuzumab + Tecentriq	solid tumors
	emactuzumab + selicrezumab	solid tumors
RG7421	Cotellic + Zelboraf + T	melanoma
	Cotellic + T	BRAF WT mM2L
RG7446	Tecentriq	solid tumors
	Tecentriq	NMIBC
	T-based Morpheus platform	pancreatic ca
	T + Cotellic ± Avastin	2/3L CRC
	T ± Avastin ± chemo	HCC, GC, PaC
	T + Cotellic	solid tumors
	T + ipi/IFN	solid tumors
	T + Tarceva/Alecensa	NSCLC
	T + anti-CD20 multiple combos	lymphoma
	T ± lenalidomide ± daratumumab	MM
	T + K/HP	HER2+ BC
	T + HMA	MDS
	T + radium 223	mCRPC
	T + guadecitabine	AML
	T + rucaparib	ovarian ca
	T + Gazyva/tazemetostat	r/r DLBCL + FL
RG7461	FAP IL2v FP + Tecentriq ± Avastin	RCC
RG7802	CEA TCB ± Tecentriq	solid tumors
RG7813	CEA IL2v FP* + Tecentriq	solid tumors
RG7828	CD20 TDB ± Tecentriq	solid tumors
RG7876	selicrelumab (CD40) + T	solid tumors
	selicrelumab + vanucizumab	solid tumors
AMGN**	Tecentriq + talimogene laherp	TNBC, CRC
BLRX**	Tecentriq + BL-8040	AML, solid tumors
CRVS**	Tecentriq + CPI-444	solid tumors
EXEL**	Tecentriq + cabozantinib	solid tumors
HALO**	Tecentriq + PEGPH20	CCC, GBC
INO**	Tecentriq + INO5401+INO9012	bladder ca
JNJ**	Tecentriq ± daratumumab	solid tumors
KITE**	Tecentriq + KTE-C19	r/r DLBCL

MORPHEUS Platform – Phase Ib/II (4 AIs)

RG7446	T-based Morpheus	pancreatic cancer
	T-based Morpheus	gastric cancer
	T-based Morpheus	HR+ BC
	T-based Morpheus	NSCLC

** External collaborations: BLRX - BioLine Rx CXCR4 antag; CRVS – Corvus ADORA2A antag; EXEL – Exelexis' TKI; Gradalis – EATC therapy; GTHX – G1 Therapeutics CDK4/6; HALO – Halozyme PEGPH20; IMDZ – Immune Design CMB305; INO - Inovio T cell activating immunotherapy (INO-5401), IL-12 activator (INO-9012); JNJ – Janssen CD38 MAb; KITE – Kite KTE-C19; AMGN – Amgen oncolytic virus; SNDX – Syndax HDAC inh

New Molecular Entity (NME)
Additional Indication (AI)
Oncology

RG-No Roche/Genentech
*INN: cergutuzumab amunaleukin
T=Tecentriq; TCB=T cell bispecific
TDB=T cell dependent bispecific

Phase II (5 AIs)

RG7421	Cotellic + Tecentriq ± taxane	TNBC
Gradalis**	Tecentriq + Vigil	ovarian ca
GTHX**	Tecentriq + trilaciclib	SCLC
IMDZ**	Tecentriq + NY-ESO-1	soft tissue sarcoma
SNDX**	Tecentriq + entinostat	TNBC

Phase III (20 AIs)

RG7421	Cotellic + Zelboraf + T	1L BRAFm melanoma
	Cotellic + Tecentriq	1L BRAF WT melanoma
RG7446	Tecentriq	NSCLC adj
	Tecentriq	MIBC adj
	Tecentriq Dx+	1L sq + non-sq SCLC
	Tecentriq	RCC adj
	T + nab-paclitaxel	1L non-sq NSCLC
	T + chemo + Avastin	1L ovarian cancer
	T + chemo + Avastin	1L non-sq NSCLC
	T + chemo + pemetrexed	1L non-sq NSCLC
	T + nab-paclitaxel	1L sq NSCLC
	T + nab-paclitaxel	1L TNBC
	T + nab-paclitaxel	TNBC neoadj
	T + Avastin	RCC
	T + Cotellic	3L CRC
	T ± chemo	1L mUC
	T + chemo	1L extensive stage SCLC
	T + enzalutamide	CRPC
	T + paclitaxel	1L TNBC
RG7446/RG7853	Tecentriq or Alecensa	1L NSCLC Dx+

Status as of February 1, 2018

Doing now what patients need next